Researchers presenting at the 2026 European Association of Urology Congress argued that prostate cancer screening yields comparable benefits to breast cancer screening across detection of clinically significant disease, mortality reduction and reduction of unnecessary interventions. The analysis—based on comparative detection metrics and outcomes data—challenged current screening disparities and calls for re‑evaluating prostate screening policy frameworks. The presenters acknowledged implementation hurdles around overdiagnosis and shared decision‑making but said evidence supports more systematic prostate screening strategies.